GLP 1 Agonists

This hub provides a comprehensive overview of GLP-1 receptor agonists, semaglutide, and related peptide therapeutics, integrating the latest scientific evidence and clinical perspectives. The linked articles examine the mechanisms of GLP-1–based therapies in weight loss, diabetes management, and beyond, as well as their emerging roles in addressing conditions such as alcohol addiction and menopause-related metabolic changes. Readers will find detailed discussions on efficacy, safety, patient selection, and the comparative potential of novel molecules like berberine. The collection also explores broader trends in peptide therapeutics and the future landscape of targeted treatment. This resource is designed for healthcare professionals, researchers, and individuals seeking authoritative, evidence-based information on GLP-1 and peptide-based interventions.

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, particularly in patients with type 2 diabetes, when combined with tailored dietary strategies. Optimizing macronutrient intake, fiber, hydration, and meal timing can enhance the therapeutic benefits of GLP-1 RAs and mitigate common gastrointestinal side effects, supporting sustainable clinical outcomes.

Overview

Explore authoritative articles on GLP-1, semaglutide, peptide therapeutics, weight loss, diabetes, and emerging treatments. This hub delivers evidence-based insights for clinicians, researchers, and anyone interested in targeted therapies.

The Potential of Peptide Therapeutics in Treating Chronic Diseases

Semaglutide and Weight Loss in Menopause

The Impact of Glucagon on Diabetes Management

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Wegovy: A Breakthrough in Weight Loss?

The Natural Molecule That Could Rival Ozempic

The Unexpected Effects of GLP-1 Medications on Women’s Health

Are GLP-1 Drugs the Future of Alcohol Addiction Treatment?

How Does Semaglutide Work to Lose Weight?

Is Berberine Really “Nature’s Ozempic”? What Science Says

See more featured articles »

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Peptide Therapy: The Future of Targeted Treatment?

Latest GLP 1 Agonists News and Research

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

17 Sep 2025

New genetic test can help predict how people will respond to weight-loss medications

Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s.

17 Sep 2025

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

Higher-dose semaglutide helps people lose nearly 19% of body weight

The STEP UP trial reveals semaglutide 7.2 mg significantly reduces weight compared to 2.4 mg, though it raises questions about gastrointestinal side effects.

16 Sep 2025

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Individuals taking semaglutide for weight loss experience less food noise than before

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.

16 Sep 2025

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.

16 Sep 2025

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight.

15 Sep 2025

Are GLP-1 drugs safe for women planning pregnancy?

A study reveals rising GLP-1 prescriptions in young women, highlighting low contraception use and potential risks for unintended pregnancies and fetal outcomes.

12 Sep 2025

Scientists uncover brain circuit that turns cravings into eating behavior

Researchers found that the bed nucleus of the stria terminalis integrates pleasure signals from central amygdala prodynorphin neurons and hunger signals from agouti-related peptide neurons to drive consumption. Manipulating this bed nucleus of the stria terminalis circuit bidirectionally altered food intake and body weight in mice.

11 Sep 2025

Study challenges conventional thinking about the onset of Type 2 diabetes

A study from The University of Texas at San Antonio Health Science Center indicates that changes in the body that lead to Type 2 diabetes occur long before current diagnostic thresholds for prediabetes are met.

11 Sep 2025

WHO expands essential medicines lists with new cancer and diabetes treatments

Today, the World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

5 Sep 2025

Semaglutide may one day be used to treat cocaine addiction

A drug already prescribed for type 2 diabetes and obesity may one day be used to treat cocaine addiction. In animal studies, researchers at the University of Gothenburg, Sweden, found that semaglutide reduced both cocaine use and relapse.

5 Sep 2025

Weight loss medication semaglutide reduces cocaine seeking behavior in animal study

Scientists have found that the diabetes/weight loss drug Semaglutide, sold commercially under brand names like Ozempic and Wegovy, significantly reduces cocaine-seeking behaviour in rats.

4 Sep 2025

$New hypothesis links internal fat biology to heart failure with preserved ejection fraction$

New hypothesis links internal fat biology to heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person's internal fat tissue, according to the Adipokine Hypothesis, a new way of understanding how fat may impact the heart.

1 Sep 2025

Increasing numbers of bariatric surgery patients turn to GLP-1 drugs

Bariatric surgery is usually effective on its own for weight loss, but an increasing proportion of patients who undergo bariatric surgery start taking one of the new glucagon-like 1 peptide receptor agonist (GLP-1) weight-loss drugs in the years after their surgery, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

27 Aug 2025

Do GLP-1 drugs shrink your muscles? New study explains the risks and what to do

GLP-1 receptor agonists are transforming obesity and diabetes care, but may reduce skeletal muscle mass, raising concerns about sarcopenic obesity. This comprehensive review explores the mechanisms, clinical implications, and mitigation strategies, including exercise, protein intake, and adjunct therapies.

26 Aug 2025

Study clarifies how amylin receptors respond to drugs

Amylin, a hormone that controls appetite and blood sugar by activating three different receptors in the brain, could be the basis for the next blockbuster obesity drugs.

19 Aug 2025